Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

The Lancet. Haematology·2026
Same author

Re: Comment on "Socioeconomic Risk Factors for Incomplete Vaccination in Swedish Two-Year-Olds-A Nationwide, Population-Based Cohort Study".

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

No Increased Risk of Cancer Death after Endovascular Aortic Repair in a Nationwide Population-based Cohort Study.

The British journal of surgery·2026
Same author

Women with Abdominal Aortic Aneurysms Have a Different Pattern of Genetic Variability, Compared to Men.

Biomedicines·2026
Same author

Total Endovascular Repair of Ascending Aortic Pathology: The ENDOASC Multicentre Global Study.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same author

Socioeconomic Risk Factors for Incomplete Vaccination in Swedish Two-Year-Olds-A Nationwide, Population-Based Cohort Study.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles
  1. Home
  3. Semaglutide Prevents Aortic Rupture And Dissection In The Angiotensin Ii Mouse Model.
  1. Home
  3. Semaglutide Prevents Aortic Rupture And Dissection In The Angiotensin Ii Mouse Model.

Related Experiment Video

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

1.3K

Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model.

Amanda Balboa Ramilo1, Kevin Mani2, Anders Wanhainen2

  • 1Department of Medical Cell Biology, Uppsala University, 751 23 Uppsala, Sweden.

Biomedicines
|May 4, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Semaglutide, a Glucagon-like peptide-1 receptor agonist (GLP-1RA), prevents early aortic rupture and dissection in a mouse model of abdominal aortic aneurysm (AAA). It may preserve vessel wall integrity by maintaining collagen content.

Keywords:
abdominal aortic aneurysmdissectionrupturesemaglutide

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.9K
Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm
05:07

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm

Published on: August 2, 2024

1.8K

Related Experiment Videos

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

1.3K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.9K
Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm
05:07

Author Spotlight: Development and Characterization of a Mouse Model for Abdominal Aortic Aneurysm

Published on: August 2, 2024

1.8K

Area of Science:

  • Vascular Biology
  • Pharmacology
  • Medical Research

Background:

  • Abdominal aortic aneurysm (AAA) is a dangerous vascular disease with no current pharmacological prevention.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show potential in reducing AAA-related risks.
  • Semaglutide, a potent GLP-1RA, warrants investigation for AAA prevention.

Purpose of the Study:

  • To investigate the preventative effects of semaglutide on AAA development and rupture.
  • To explore the underlying mechanisms of semaglutide's action in a murine AAA model.

Main Methods:

  • AAA was induced in apolipoprotein-E-deficient mice using angiotensin II infusion.
  • Mice received semaglutide either prophylactically or as a rescue treatment.
  • Aortic diameter was measured via ultrasound, and aortic tissue underwent histological analysis.

Main Results:

  • Prophylactic semaglutide significantly reduced early mortality from rupture and dissection.
  • AAA formation at 28 days was not affected by semaglutide treatment.
  • Histology at day seven indicated preserved vessel wall thickness and a trend towards increased collagen content with semaglutide.

Conclusions:

  • Semaglutide demonstrates efficacy in preventing early aortic rupture and dissection in an angiotensin II-induced AAA mouse model.
  • The protective effect may be attributed to semaglutide's role in maintaining collagen proportion in the early stages of AAA development.